Replies to post #437913 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

As opposed to the real $AVXL down turn?

I think SAVA is a fake rally right now.

Makes sense, two sides of the same argument.

[Hoskuld]

If Simufilam and 2-73 both work then both will be prescribed. This is not a winner-take-all indication unless someone actually comes up with a true cure.

SAVA has 14 months to go before TLR are released and there is no news expected between now and then, so there will be a lot of volatility during that period - SAVA could be 30 or 10...who knows?

[scorman1]

fake rally or not, I booked 3k at $12.50 on the way to. $300 ...upstream/downstream it works and will get approval first....different MOA
Rett had better not be a blow out.

[Graniteguy]

That’s my contention as well.

[crescentmotor]

It's downstream from us so once we're approved and on our way it will basically render Sava useless.

Doesn't work that way--totally different MOAs and Simufilam's has now been validated by several independent laboratories.

[crescentmotor]

I think SAVA is a fake rally right now.

A fake rally that has added, so far, $626 million on heavy volume to SAVA's market cap? No--what happened was a fundamental change in the perception of SAVA due to the exposure of CUNY's illegally leaked report of its investigative committee, which committee is now going to be investigated for bias and possible fraud. That's a market moving development that virtually assures that SAVA's two fully enrolled Phase III trials will continue until completion. SAVA's enemies have tried for two years to get the FDA to stop SAVA's advanced trials through the Citizens Petitions and by other means. Now the Street perceives that won't happen--and the price moved significantly higher with the elimination of the negative overhang. The next legal development may be a negotiated settlement of all the related court proceedings. Then again, maybe SAVA will continue its ongoing separate lawsuit against the short players due to the tremendous loss in market capitalization caused by the bogus claims. Big picture: all that really matters now is the completion in fall 2024 of the RETHINK Phase III trial.